Roche appointing Genentech’s CEO to lead its pharma division and Mylan’s CFO leaving after three months in the job – People on the move
Pascal Soriot, the current CEO of Genetech, has been appointed to lead Roche’s pharma division. Soriot, who has played a significant role in integrating the companies, will take the title of chief operating officer of the pharma division.
Ian Clark, currently head, global product strategy, pharma, will replace Soriot as CEO of Genentech. Roche has also appointed Jean-Jacques Garaud and Dan Zabrowski to the enlarged executive committee.
Mylan has decided to “part ways” with its chief financial officer (CFO) Jolene Varney three months after she was appointed. No reason was given for the departure that was revealed in a one paragraph press release. Mylan has engaged an executive recruiting firm to find a replacement.
John Savin has been appointed as vice president (VP) at GENova Biotherapeutics. Savin has more than 20 years experience at companies including Glaxo, Zeneca and Pharmacia Biotech.
Hovione has appointed Terry Lambe to its board of directors. Lambe retired in 2008 having worked at Pfizer for 30 years, during which time he was responsible for the construction of active pharmaceutical ingredient facilities in Puerto Rico, the US and Singapore.
Edward Harlow has been appointed as chief scientific officer at Constellation Pharmaceuticals. Harlow has previously worked with companies including Onyx, 3V Biosciences and Pfizer.
Ritter Pharmaceuticals has appointed Howard Foyt as executive VP, development and chief medical officer. Foyt has more than 13 years experience in drug development at companies including Metabasis Therapeutics, Pfizer and Parke-Davis.
Neil Covey has been appointed to the board of directors at Stirling Products. Covey has previously worked at Astra, Knoll Pharmaceuticals and Bayer.
